BHP Attracts AI-Focused Investors as Copper Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
NEW YORK, May 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) securities between August 13, 2014 and March 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
